Mutated NPM1 is a promising and potential target for NPM1-mutated AML because the NPM1-mutated protein does not exist in normal tissues, and therefore, it is an ideal leukemia-specific antigen (LSA). This evidence concerns the gene NPM1 and acute myeloid leukemia.